Garland Surgical Ltd.

Garland Surgical Ltd. , based in the UK, specializes in developing innovative hip implants that enhance patient mobility and stability during hip replacement surgeries. Garland Surgical Ltd. , founded in 2022 in the UK, focuses on the development and commercialization of advanced hip implant technologies.

The company has engaged in three significant deals up to now, with its latest funding round being a Grant of EUR 1. 4 million from Malta Enterprise on May 22, 2026. This funding will support the progress of their hip replacement system, emphasizing product development and regulatory preparations. The founder's details are not available.

Garland Surgical Limited specializes in the development and commercialization of the TriActiv Hip, a next-generation hip implant designed to enhance mobility, stability, and durability for patients undergoing hip replacement surgery. Utilizing a patented tri-axial design, the TriActiv Hip offers a unique articulation system that allows for three degrees of freedom, thereby mimicking natural hip movement while significantly increasing stability and reducing wear. The flagship product comprises two variations: the TriActiv Monoblock implant, which integrates a polymer liner within a 3D-printed titanium shell, and the TriActiv Modular implant, featuring a snap-on liner that can be positioned to optimize joint mechanics. These implants are intended for diverse patient demographics, including those suffering from hip arthritis, and are being developed for entry into the U.

S. market through FDA 510(k) clearance, with plans to expand globally. The company primarily targets healthcare institutions and orthopedic surgeons in major markets such as the United States and Europe. Garland Surgical Limited generates revenue through the sale of its TriActiv Hip implants to healthcare facilities and orthopedic practices, establishing a direct-to-consumer business model.

The transaction structure is primarily business-to-business, with contracts negotiated between Garland Surgical and hospitals or clinics that perform hip replacement surgeries. The company’s revenue is bolstered by its strategic partnerships with leading manufacturers for production and distribution, aimed at ensuring efficient delivery of products. Revenue streams may also include potential licensing agreements as the company expands its market presence, particularly with anticipated growth in the hip replacement sector projected to reach USD 11. 2 bn by 2034.

Specific pricing details for the TriActiv Hip implants are proprietary to Garland Surgical and not publicly disclosed. In May 2026, Garland Surgical raised EUR 1. 4 million of grant funding from Malta Enterprise to advance its hip replacement system. The funding will be utilized for product development, regulatory preparation, and initial clinical activities, ensuring a strategic foundation for future growth.

Garland Surgical plans to enhance its product line with new innovations in hip implant technology and is focused on entering new markets, including the U. S. , with regulatory efforts aimed at obtaining necessary approvals by the end of 2026.